10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2010 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 18, 2011) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Cash Flow From (Used in) Operating Activities of Continuing Operations: | |||
| Net earnings | $ 4,626,172 | 5,745,838 | 4,880,719 |
| Less: Gain on sale of discontinued operations | 146,503 | ||
| Earnings from continuing operations | 4,626,172 | 5,745,838 | 4,734,216 |
| Adjustments to reconcile earnings from continuing operations to net cash from operating activities of continuing operations - | |||
| Depreciation | 1,207,450 | 1,210,977 | 1,051,728 |
| Amortization of intangible assets | 1,416,855 | 878,533 | 787,101 |
| Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture | (797,130) | ||
| Share-based compensation | 387,183 | 366,357 | 347,015 |
| Gain on dissolution of the TAP Pharmaceutical Products Inc. joint venture | (94,248) | ||
| Acquired in-process research and development | 313,200 | 170,000 | 97,256 |
| Investing and financing (gains) losses, net | 126,337 | 41,967 | 111,238 |
| Trade receivables | (394,665) | (387,749) | (948,314) |
| Inventories | 139,857 | 230,555 | (257,476) |
| Prepaid expenses and other assets | 553,145 | (386,889) | 436,218 |
| Trade accounts payable and other liabilities | 572,533 | (374,715) | 569,056 |
| Income taxes | (212,086) | 577,416 | 160,830 |
| Net Cash From Operating Activities of Continuing Operations | 8,735,981 | 7,275,160 | 6,994,620 |
| Cash Flow From (Used in) Investing Activities of Continuing Operations: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (9,433,243) | (2,370,630) | (250,000) |
| Acquisitions of property and equipment | (1,015,075) | (1,089,048) | (1,287,724) |
| Sales of Boston Scientific common stock | 318,645 | ||
| Purchases of investment securities | (805,932) | (248,970) | (923,937) |
| Proceeds from sales of investment securities | 954,361 | 16,306 | 130,586 |
| Deposit of restricted funds | (1,870,000) | ||
| Other | (18,426) | (6,368) | (75,061) |
| Net Cash (Used in) Investing Activities of Continuing Operations | (12,188,315) | (3,698,710) | (2,087,491) |
| Cash Flow From (Used in) Financing Activities of Continuing Operations: | |||
| (Repayments of) proceeds from issuance of short-term debt and other | (203,854) | 3,217,331 | (324,739) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 4,000,000 | 3,000,000 | |
| Repayments of long-term debt and debt with maturities over 3 months | (1,673,998) | (2,483,176) | (913,948) |
| Purchases of common shares | (866,825) | (826,345) | (1,081,806) |
| Proceeds from stock options exercised, including income tax benefit | 328,411 | 508,669 | 1,008,843 |
| Dividends paid | (2,671,475) | (2,414,460) | (2,174,252) |
| Net Cash (Used in) From Financing Activities of Continuing Operations | (1,087,741) | 1,002,019 | (3,485,902) |
| Effect of exchange rate changes on cash and cash equivalents | (620,893) | 118,848 | (115,160) |
| Net cash provided from the sale of discontinued operations | 349,571 | ||
| Net (Decrease) Increase in Cash and Cash Equivalents | (5,160,968) | 4,697,317 | 1,655,638 |
| Cash and Cash Equivalents, Beginning of Year | 8,809,339 | 4,112,022 | |
| Cash and Cash Equivalents, End of Year | 3,648,371 | 8,809,339 | 4,112,022 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |